focus -WSS

focus

author：leisure time 2025-10-03 00:40:50 - browse：39

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Videos point to link between seizures and unexplained toddler deaths

hotspot

WSS

In same hospitals, Black patients receive fewer opioids than white patients

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

UCB departs biotech trade group BIO

NIH trials fail to test meaningful long Covid therapies, experts say

GSK Flovent asthma inhalers replaced by authorized generics

focus

focus

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

UCB departs biotech trade group BIO

Affirmative action in medical school literally saved lives

Friends ask where James Watson's attitudes about race came from

Bright Health sells Medicare Advantage business to Molina

3 trends to watch in health tech's hiring outlook for 2024

How one medical school became remarkably diverse

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

How one medical school became remarkably diverse

Feng Zhang CRISPR delivery startup lays off quarter of staff

leisure time

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Feng Zhang CRISPR delivery startup lays off quarter of staff

Drastic changes should bring profitability, startup health insurers say

Emergent cuts jobs, executive role in business shake

How a scoliosis diagnosis changed the life of one young dancer

Wegovy trial has doctors encouraged over new possibilities

hotspot

hotspot

focus

focus